Zile, M. R., Abraham, W. T., Lindenfeld, J., Weaver, F. A., Zannad, F., Graves, T., … Galle, E. G. (2018). First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF. American Heart Journal, 204, 139–150. https://doi.org/10.1016/j.ahj.2018.07.011

Zile, Michael R., William T. Abraham, JoAnn Lindenfeld, Fred A. Weaver, Faiez Zannad, Todd Graves, Tyson Rogers, and Elizabeth G. Galle. “First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF.” American Heart Journal 204 (October 2018): 139–50. https://doi.org/10.1016/j.ahj.2018.07.011.

Zile MR, Abraham WT, Lindenfeld J, Weaver FA, Zannad F, Graves T, et al. First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF. American Heart Journal. 2018 Oct;204:139–50.

Zile, Michael R., et al. “First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF.” American Heart Journal, vol. 204, Elsevier BV, Oct. 2018, pp. 139–50. Crossref, doi:10.1016/j.ahj.2018.07.011.

Zile MR, Abraham WT, Lindenfeld J, Weaver FA, Zannad F, Graves T, Rogers T, Galle EG. First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF. American Heart Journal. Elsevier BV; 2018 Oct;204:139–150.